Weekly Research Analysts’ Ratings Updates for Revolution Medicines (RVMD)

Several analysts have recently updated their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 8/31/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by UBS Group AG from $220.00 to $265.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by Guggenheim from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $203.00 to $251.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $248.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Oppenheimer Holdings, Inc. from $230.00 to $260.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $320.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by HC Wainwright from $195.00 to $280.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Wedbush from $201.00 to $225.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $231.00 to $239.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Revolution Medicines was upgraded by TD Cowen to “strong-buy”.
• 8/21/2026 – Revolution Medicines had its price target raised by Sanford C. Bernstein from $151.00 to $179.00. They now have a “market perform” rating on the stock.
• 8/11/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $210.00 to $231.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wolfe Research. They now have a $220.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Wedbush from $192.10 to $201.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $182.00 to $203.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Guggenheim from $235.00 to $240.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $236.00 to $240.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Revolution Medicines had its price target raised by Wedbush from $181.00 to $192.10. They now have an “outperform” rating on the stock.
• 7/20/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $235.00 to $236.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Revolution Medicines had its price target raised by Guggenheim from $205.00 to $235.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Revolution Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $195.00 price target on the stock.
• 7/6/2026 – Revolution Medicines had its price target raised by Mizuho from $185.00 to $215.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling

In other news, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the completion of the transaction, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the sale, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 268,497 shares of company stock worth $49,587,926. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.